May 10, 2019

Treatment to restore natural heartbeat could be on the horizon for heart failure

Posted by in category: biotech/medical

A new therapy to re-engage the heart’s natural electrical pathways—instead of bypassing them—could mean more treatment options for heart failure patients who also suffer from electrical disturbances, such as arrhythmias, according to research led by the University of Chicago Medicine.

In a first-ever , called the His SYNC trial, researchers compared the effectiveness of two different cardiac resynchronization therapies, or treatments to correct irregularities in the heartbeat through implanted pacemakers and defibrillators. The current standard of care, known as biventricular pacing, uses two pacing impulses in both lower chambers, whereas the newer approach, called His bundle pacing, attempts to work toward engaging and restoring the heart’s natural physiology. The two approaches have never before been directly compared in a head-to-head clinical trial.

“This is the first prospective study in our field to compare outcomes between different ways to achieve cardiac resynchronization,” said cardiologist Roderick Tung, MD, FHRS, the Director of Cardiac Electrophysiology & EP Laboratories at the University of Chicago Medicine. “Through His bundle pacing, we’re trying to tap into the normal wiring of the heart and restore conduction the way nature intended. Previously, we have just accepted that we had to bypass it through pacing two ventricles at a time.”

Read more

Comments are closed.